Spring Sale: Up to 50% OFF · Ends Tonight

Does Wegovy Cause Hair Loss? FDA Data & Real-World Evidence

Updated 2026-04-17 10 min read By Provant Labs Research Team

Yes, Wegovy causes hair loss. The FDA prescribing information for semaglutide 2.4mg reports alopecia in 3% of treated adults versus 1% of placebo patients. In women who lost more than 20% of body weight, the rate climbs to 5.3%. Real-world estimates from clinical practice run 25-33% of women on the medication. Here's every piece of data, named and sourced.

What the Wegovy FDA Label Actually Says

The official Wegovy prescribing information (semaglutide 2.4mg subcutaneous, weekly) lists alopecia as an adverse reaction in the clinical trials section. These aren't anecdotal reports. These are systematically documented adverse events from Phase 3 randomized controlled trials.

The numbers:

That dose-response pattern is important. The drug doesn't cause hair loss at a flat rate. The more weight you lose, the more likely you are to shed. This is what you'd expect if rapid weight loss, rather than semaglutide itself, is the primary trigger.

A note on Ozempic vs Wegovy: Ozempic is semaglutide for diabetes at a lower dose (up to 2mg weekly). Its prescribing information doesn't list alopecia as prominently. The clear hair loss signal comes from the obesity trials, where weight loss is faster and more dramatic. Same molecule, different context.

The OASIS 1 Trial: 6.9%

The OASIS 1 trial (Knop et al., Lancet 2023) tested oral semaglutide 50mg daily in a weight management population.

That 6.9% is more than double the injectable Wegovy label figure. Oral semaglutide at 50mg produced aggressive weight loss in this Phase 3 RCT, which likely explains the higher hair loss rate. It also represents the clearest upper-bound estimate from controlled Wegovy-class trial data.

Real-World Data: Etminan et al. 2025

Clinical trials document what happens under structured observation. Real-world data tells you what happens in actual clinical practice.

Etminan et al. 2025 (medRxiv preprint) examined 1,926 semaglutide users versus 1,348 patients on bupropion-naltrexone (a different weight loss medication), tracking hair loss outcomes in both groups.

Key findings:

The HR of 2.08 means women on semaglutide had more than twice the hair loss event rate compared to women on a different active weight loss treatment. Not compared to untreated patients. Compared to another drug for obesity.

And men? The signal essentially disappears. HR 0.86. Not significant.

This study is one of the clearest pieces of evidence that Wegovy's hair loss risk is concentrated in women, and that it's not simply a weight-loss effect that would occur with any treatment.

Why Women Are Affected So Much More

The sex-specific data across every source points in the same direction. The question is why.

Three mechanisms are well-supported:

1. Hormonal shifts. GLP-1 medications reduce LH (luteinizing hormone) and FSH (follicle-stimulating hormone). Lower LH/FSH means lower estrogen production. This hormonal shift mimics what happens after childbirth, when estrogen drops sharply and triggers the same type of diffuse shedding (telogen effluvium). Women have more estrogen to lose. Men don't.

2. Hair cycle vulnerability. Women's hair follicles are more sensitive to systemic stress. The same rapid weight loss that might not affect a man's hair can shift up to 30-50% of a woman's follicles from active growth (anagen) into the resting phase (telogen) simultaneously. Normal daily shedding is 100-150 hairs. During telogen effluvium, weeks' worth of resting follicles release at once.

3. Usage patterns. Women are more likely to be prescribed GLP-1 medications for obesity (the highest-use group is women aged 50-64, approximately 1 in 5 of that demographic). More women on the drug means more observations of hair loss in women, but the biological mechanisms above are independent of this.

Pharmacovigilance: Godfrey et al. 2025

The FDA Adverse Event Reporting System (FAERS) captures spontaneous reports from patients and healthcare providers. These aren't controlled trial outcomes, but they identify whether a drug-event combination is reported at higher-than-expected rates.

Godfrey et al. 2025 (Journal of the European Academy of Venereology and Dermatology) analyzed FAERS data from 2022-2023, covering 469 alopecia reports.

Results:

An ROR above 1.0 means the combination is reported more frequently than chance in the full database. Semaglutide's 2.46 is a strong signal, placing it among drugs with clear pharmacovigilance evidence for this adverse event. The consumer-driven reporting (84%) reflects a side effect that patients notice and report directly, often before it enters formal clinical records.

The TriNetX Cohort: n=547,993

The TriNetX multicenter cohort study used data from 67 healthcare organizations covering more than 100 million patients. Matched cohorts of 547,993 GLP-1 users vs non-users were followed for 12 months.

Results at 12 months:

This is the largest matched cohort on this question. And it finds elevated odds for three distinct hair loss diagnoses. Not just temporary shedding. The androgenic alopecia signal (1.64) is notable because androgenic alopecia is a progressive condition, not a temporary stress response.

What Telogen Effluvium Actually Is

Telogen effluvium (TE) is the clinical name for the shedding pattern most commonly associated with Wegovy use. Here's what it means in plain terms.

Hair follicles cycle through three phases: anagen (active growth, 2-8 years, 85-95% of follicles at any time), catagen (transition, a few weeks, less than 1% of follicles), and telogen (rest, 2-3 months, 4-14% of follicles). During telogen, the follicle holds a club hair that eventually falls out as a new anagen hair begins growing behind it.

Rapid weight loss tells the body it's under metabolic stress. The hair follicle, which has the highest cell division rate of any tissue in the body, gets downregulated. A large proportion of follicles shift from anagen to telogen simultaneously. Two to four months later, they all release their club hairs at once.

That's the clumps in the shower. That's the hair on the pillow. That's why it starts months after you began the medication, not immediately.

The Annals of Dermatology 2024 retrospective cohort study (n=140) quantified this: average onset of shedding 1.12 months after weight loss begins, average recovery 4.83 months after the trigger stabilizes. Without any intervention. In women who lost an average of 15.21% of body weight at 3.54 kg per month.

But here's the thing most people get wrong: when you're still actively losing weight on Wegovy, the trigger isn't stopping. It's continuous. Which is why women describe "months of shedding" rather than a single acute wave.

The 3% vs 33% Gap Explained

The FDA says 3%. Endocrinologists say 25-33%. Both are giving honest answers.

The trial figure (3%) captures alopecia that participants reported to investigators during scheduled visits, that investigators found significant enough to formally code as an adverse event, and that passed through the adverse event classification process. Women who noticed thinning between visits but didn't bring it up aren't counted. Women who mentioned it to their prescriber after the data cutoff aren't counted. The OASIS 1 trial, which was actively measuring this outcome, found 6.9%.

The 25-33% figure comes from what prescribers observe across thousands of patients: the follow-up calls between visits, the patients asking what to do, the visible difference at the 6-month appointment. It's also consistent with what Reddit communities (r/Ozempic, r/Semaglutide, r/FemaleHairLoss) document at massive scale.

The Etminan 2025 incidence rate of 26.5 per 1,000 person-years in women provides a real-world anchor between the two extremes.

Is the Hair Loss Permanent?

For most women, no. Telogen effluvium from weight loss is temporary. The follicles aren't destroyed. They've been pushed into a resting phase and will re-enter the growth cycle once metabolic conditions stabilize.

The Annals of Dermatology 2024 data (n=140) found average recovery of 4.83 months after the trigger stabilizes, ranging from 0.5 to 16 months across individuals. The wide range matters. Some women recover quickly once weight plateaus. Others experience a prolonged recovery, especially those with concurrent iron deficiency (ferritin below 30 ng/mL is strongly linked to extended hair loss), zinc depletion, or underlying androgenic alopecia that the weight loss exposed.

That androgenic alopecia finding in the TriNetX cohort (aOR 1.64) suggests that for some women, the Wegovy hair loss isn't purely TE. It may be uncovering or accelerating an underlying genetic hair loss pattern. That type doesn't self-resolve.

The practical answer: if you're still actively losing weight, the trigger is ongoing. Recovery begins when your weight stabilizes and your nutritional status recovers.

What You Can Do While Still on Wegovy

The evidence supports several approaches, none of which require stopping your medication.

Protein intake. Hair follicles are primarily protein. GLP-1 medications suppress appetite, which makes hitting protein targets harder. Aim for 60-100g daily. Many women on Wegovy undershoot this significantly.

Iron and ferritin. Ferritin below 30 ng/mL is strongly associated with telogen effluvium. A basic blood panel (ferritin, iron, TIBC) identifies this. It's correctable with supplementation.

Scalp support. Topical ingredients with clinical evidence, including rosemary extract, saw palmetto, and bioactive peptides, work directly on the follicle environment rather than through systemic absorption. Rosemary oil matched minoxidil 2% in a head-to-head randomized trial (Panahi et al., SKINmed 2015, n=100), and saw palmetto reduced shedding by 22.19% in an RCT (Sudeep et al., CCID 2023, n=80). The PD-5 Complex combines these with additional bioactive peptides in a topical formula developed specifically for GLP-1-related shedding.

Timeline management. The shedding you see today reflects follicles that entered telogen 2-4 months ago. Supporting the follicles now affects regrowth over the next 3-6 months. Starting earlier in the shedding cycle produces better outcomes than waiting for the shedding to stop on its own.

The complete Ozempic hair loss guide covers the mechanism, timeline, and full evidence base for interventions. The GLP-1 hair loss guide compares all the medications and their specific data.

FAQ

Does Wegovy definitely cause hair loss, or is it just the weight loss?

Both are involved, but rapid weight loss is the primary driver. The Wegovy FDA label shows a direct correlation: patients losing more than 20% of body weight had a 5.3% alopecia rate versus 2.5% for those losing less than 20%. The mechanism is telogen effluvium triggered by metabolic stress, not a direct drug toxicity to follicles. Semaglutide's effect on LH and FSH, which lowers estrogen, is a secondary factor that's particularly relevant to women.

What percentage of women on Wegovy lose hair?

The FDA Wegovy label reports 3% vs 1% placebo. The OASIS 1 trial (Lancet 2023, oral semaglutide) found 6.9%. The Etminan 2025 real-world cohort found women on semaglutide had HR 2.08 vs a comparator drug, with an incidence rate of 26.5 per 1,000 person-years. Clinical practice estimates run 25-33%. The wide range reflects the gap between formal trial documentation and real-world observation.

When does hair loss start on Wegovy?

The Annals of Dermatology 2024 retrospective study (n=140) found average onset 1.12 months after weight loss begins. The typical telogen effluvium pattern starts 2-4 months after the trigger, which may differ slightly from when weight loss begins. Some women notice it earlier, some later. The shedding often intensifies as weight loss accelerates.

Will my hair grow back after stopping Wegovy?

For most women, yes. Telogen effluvium from weight loss is reversible. Average recovery was 4.83 months after the trigger stabilized in the Annals of Dermatology 2024 data, though the range ran 0.5 to 16 months. Women with concurrent iron deficiency or underlying androgenic alopecia may experience longer recovery. Follicles pushed into telogen re-enter the growth cycle once metabolic conditions normalize.

Should I stop Wegovy because of hair loss?

That's a decision to make with your prescriber, not alone. Hair loss was cited as the primary reason some women stopped GLP-1 medications in patient surveys. But the metabolic benefits of these medications for weight management, blood sugar, and cardiovascular risk are clinically significant. Temporary hair loss versus long-term metabolic health is a trade-off worth discussing carefully. Most women find the hair loss manageable when they understand the mechanism and address it directly rather than stopping the medication.

Does hair loss get worse with higher Wegovy doses?

The data suggests yes. The dose-response relationship in the FDA label (5.3% at more than 20% weight loss vs 2.5% at less than 20%) is indirect evidence: higher doses produce more weight loss, which produces more shedding. The OASIS 1 trial's 6.9% rate at 50mg oral semaglutide, the highest dose tested, supports this pattern.

Ready to support your hair during your GLP-1 journey?

See the PD-5 Complex